Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
复制标题
DOI：
10.1053/j.ajkd.2004.11.004
复制
发表时间：
2005-03-01
影响因子：
13.2
通讯作者：
Steiner, G
中科院分区：
文献类型：
--
作者：
Ansquer, JC;Foucher, C;Steiner, G
背景：微量白蛋白尿是糖尿病肾病的早期标志物，也是心血管疾病的独立危险因素。在糖尿病动脉粥样硬化干预研究（DAIS）中，与安慰剂相比，用微粒化非诺贝特治疗2型糖尿病患者平均38个月，减少了血管造影评估的冠状动脉疾病的进展，并改善了脂蛋白水平异常。本分析的目的是研究治疗对尿白蛋白排泄变化的影响。研究方法：在314名DAIS参与者（77名女性，237名男性;平均年龄56岁）中，通过在基线和此后每年使用定时过夜样本测量2 - 3次微量白蛋白尿;除3名参与者外，所有参与者的白蛋白排泄率均正常（
Background: Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease. In the Diabetes Atherosclerosis Intervention Study (DAIS), treatment of people with type 2 diabetes with micronized fenofibrate for an average of 38 months reduced the progression of angiographically evaluated coronary artery disease and improved lipoprotein level abnormalities compared with placebo. The aim of this analysis is to study the influence of the treatment on changes in urinary albumin excretion. Methods: Microalbuminuria was measured on 2 to 3 occasions by using timed overnight samples at baseline and yearly thereafter in 314 DAIS participants (77 women, 237 men; average age, 56 years); all except 3 participants had either a normal albumin excretion rate (